2/25
08:00 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $64.00 price target on the stock.
High
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $64.00 price target on the stock.
2/19
12:14 pm
urgn
Rating for URGN
Low
Report
Rating for URGN